Inhibition of the lysyl oxidase family using a small-molecule inhibitor offers several benefits that target the tumor-associated stroma at several stages of cancer progression, including improved chemotherapy response, reduced metastatic burden and prolonged survival. The gene discussed is LOX; the disease is neoplasm.